经典永流传-Pit Pattern分类,测一测你能否正确诊断?

2020-04-15 com0707 一泓小树林

经典永流传-Pit Pattern分类,测一测你能否正确诊断?

图1 Pit Pattern 放大色素内镜分类

图2 Pit Pattern 色素内镜分类

Pit Pattern I型

图3 结肠正常黏膜放大图像,可见圆形小pit,为正常隐窝。

Pit Pattern II型

图4 典型的 pit pattern II型,具有星形或洋葱皮状结构(左),II型开放 pit pattern由于黏液生成导致隐窝打开是SSA/P的特征(右)。

Pit Pattern IIIs型

图5 pit pattern III型由小的管状或圆形pits组成,比正常黏膜周围的隐窝小。

Pit Pattern IIIL型

图5 pit pattern IIIL型由长管状隐窝组成(左),有时在内部区域与正常隐窝混合在一起(右)。

Pit Pattern IV型

图6 pit pattern IV型为沟状、分支状或脑回样的表面结构。

Pit Pattern VI型

图7 pit pattern VI型与IIIL、IIIS和IV型类似,但由无序性、大小不等、不对称的腺管等组成。轻度不规则的称为“低级”(左),高度不规则的为“高级”(右)。

Pit Pattern VN型

图8 pit pattern VN型指表面结构丢失(左侧)或破坏(右侧) 。

Pit Pattern分类的意义

内镜诊断是内镜最重要的组成部分。使用放大内镜用于“Pit诊断”,更接近病理诊断。在Pit Pattern分类中,肿瘤与非肿瘤之间的正确诊断率约为96%~98%,腺瘤与癌症之间的正确识别率约为70%~90%。在黏膜下浸润癌中,血管浸润和淋巴结转移的风险与肿瘤的垂直浸润(T1)成正比。因此,在内镜下治疗早期结直肠癌之前,有必要对其浸润深度进行诊断。放大内镜显示,当作为Vn型黏膜下层侵犯的指标时,正确的识别率约为90%。因此,用放大内镜可以获得高精度的定性诊断。

白光+NBI


白光+NBI


白光+靛胭脂


白光内镜 CF-HQ290I


NBI CF-HQ290I


靛胭脂 CF-HQ290I

以下几张图片你的诊断是腺管分型?绒毛管状腺瘤或者TSA?

白光内镜 CF-H260I


NBI CF-H260I


靛胭脂 CF-H260I


NBI CF-H260I


甲紫染色 CF-H260I

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786787, encodeId=d8a01e8678733, content=<a href='/topic/show?id=9bb7138035c' target=_blank style='color:#2F92EE;'>#pattern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13803, encryptionId=9bb7138035c, topicName=pattern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Fri Mar 19 17:30:12 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884948, encodeId=fced88494826, content=高压, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Sep 13 14:22:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935473, encodeId=866319354e3c4, content=<a href='/topic/show?id=a591143050d' target=_blank style='color:#2F92EE;'>#Pit Pattern分类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14305, encryptionId=a591143050d, topicName=Pit Pattern分类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89da2500024, createdName=1194695146_61857347, createdTime=Sat May 02 15:30:12 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038415, encodeId=67e52038415b5, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun May 24 09:30:12 CST 2020, time=2020-05-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786787, encodeId=d8a01e8678733, content=<a href='/topic/show?id=9bb7138035c' target=_blank style='color:#2F92EE;'>#pattern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13803, encryptionId=9bb7138035c, topicName=pattern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Fri Mar 19 17:30:12 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884948, encodeId=fced88494826, content=高压, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Sep 13 14:22:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935473, encodeId=866319354e3c4, content=<a href='/topic/show?id=a591143050d' target=_blank style='color:#2F92EE;'>#Pit Pattern分类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14305, encryptionId=a591143050d, topicName=Pit Pattern分类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89da2500024, createdName=1194695146_61857347, createdTime=Sat May 02 15:30:12 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038415, encodeId=67e52038415b5, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun May 24 09:30:12 CST 2020, time=2020-05-24, status=1, ipAttribution=)]
    2020-09-13 ms1000000302953060

    高压

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1786787, encodeId=d8a01e8678733, content=<a href='/topic/show?id=9bb7138035c' target=_blank style='color:#2F92EE;'>#pattern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13803, encryptionId=9bb7138035c, topicName=pattern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Fri Mar 19 17:30:12 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884948, encodeId=fced88494826, content=高压, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Sep 13 14:22:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935473, encodeId=866319354e3c4, content=<a href='/topic/show?id=a591143050d' target=_blank style='color:#2F92EE;'>#Pit Pattern分类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14305, encryptionId=a591143050d, topicName=Pit Pattern分类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89da2500024, createdName=1194695146_61857347, createdTime=Sat May 02 15:30:12 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038415, encodeId=67e52038415b5, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun May 24 09:30:12 CST 2020, time=2020-05-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786787, encodeId=d8a01e8678733, content=<a href='/topic/show?id=9bb7138035c' target=_blank style='color:#2F92EE;'>#pattern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13803, encryptionId=9bb7138035c, topicName=pattern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Fri Mar 19 17:30:12 CST 2021, time=2021-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884948, encodeId=fced88494826, content=高压, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Sep 13 14:22:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935473, encodeId=866319354e3c4, content=<a href='/topic/show?id=a591143050d' target=_blank style='color:#2F92EE;'>#Pit Pattern分类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14305, encryptionId=a591143050d, topicName=Pit Pattern分类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89da2500024, createdName=1194695146_61857347, createdTime=Sat May 02 15:30:12 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038415, encodeId=67e52038415b5, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun May 24 09:30:12 CST 2020, time=2020-05-24, status=1, ipAttribution=)]

拓展阅读

西安交大徐峰/海南人民医院刘娜/西安交大二附院王进海团队:基质物理特性通过整合素介导的细胞-ECM相互作用调控胃癌进展

该研究首次系统性表征了胃癌物理微环境,揭示了基质物理特性在胃癌恶性进展中先前未确定的作用,增加了人们对细胞-ECM力学双向相互作用的深入了解,为联合力医学的胃癌个体化治疗提供了新的治疗靶点和治疗策略。

【衡道丨笔记】精准医学时代胃癌外科治疗的挑战和思考——从标准化到个体化

“复旦大学附属中山医院病理科32周年系列公开课”的课程中,张恒老师为大家带来了精准医学时代胃癌外科治疗的挑战和思考——从标准化到个体化的内容。摘要如下:

论文解读|Hongjuan Cui/Xiaoxue Ke/MuHan Lü教授团队揭示PRMT1促进胃癌增殖和转移的新机制

该研究揭示了PRMT1通过与MLXIP和KTN1的相互作用促进胃癌细胞的增殖和转移,为胃癌治疗提供了新的靶点。

【论著】| 曲妥珠单抗辅助改良DOF双周方案对顺铂耐药的胃癌患者血清肿瘤标志物及生存率的影响分析

本研究旨在探讨联合治疗方案对肿瘤标志物和生存率的影响,以期为顺铂耐药的胃癌患者的临床治疗方案选择提供参考。

【专题论著】| 以大型单中心医院登记为基础的6 737例接受手术切除的胃癌患者的生存报告

本研究为了解中国胃癌患者的生存情况提供来自真实世界的数据,反映中国经济发达地区的胃癌诊治水平,为中国的胃癌防控和政策制定提供科学依据。

大咖谈 | HER2-阴性晚期胃癌一线治疗策略

帕博利珠单抗在2023年12月中国境内获批帕博利珠单抗联合含氟尿嘧啶类和铂类药物化疗用于局部晚期不可切除或转移性HER2-阴性胃或胃食管结合部腺癌患者的一线治疗。